Phase 2 Study of Cabozantinib for Treating Recurrent Liver Cancer After Liver Transplant

What this Trial Is About

Researchers are evaluating the investigational drug cabozantinib in patients with hepatocellular carcinoma, a type of liver cancer, who have had a liver transplant but whose cancer has returned. This phase 2 study aims to see how effective cabozantinib is in controlling the disease in these patients by blocking certain proteins that help cancer tumors grow. Participants will take cabozantinib orally at a dose of 60 mg once daily at bedtime, continuously until the drug no longer benefits them or side effects become intolerable. The study includes three parts screening to assess safety and eligibility, the treatment period with weekly clinic visits for tests and assessments, and follow-up visits every 8 weeks after treatment ends. If side effects occur, participants will be monitored weekly for about 4 weeks, then monthly until stable. During the study, participants will undergo various tests and procedures to monitor their health and disease status, including safety assessments and research-only evaluations. The primary outcome measured is disease control rate at 4 months, with secondary outcomes including progression-free survival, overall survival, and side effects over 3 years. Participants will be followed closely throughout the study period, which continues until June 2026.

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant